

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Maureen Wallerhost Examiner #: 704165 Date: 4-23-02
 Art Unit: 1743 Phone Number 308-3912 Serial Number: 09/800,689
 Mail Box and Bldg/Room Location: CP3-7A01 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Automated Immunohistochemical + In Situ Hybridization

Inventors (please provide full names): Penny Towne Assay Formulations
+ Joseph Utermohlen

Earliest Priority Filing Date: 3/7/01

**For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

Please search for a composition comprising

- 1) citrate buffer (broad - just buffer)
- 2) ethylene glycol (broad - ^{just} glycol)
- 3) sodium metabisulfite (or sodium bisulfite)
- 4) sodium dodecyl sulfate (SDS)

See claims 1, 13 and 20

STAFF USE ONLY

Searcher: EN

Searcher Phone #: _____

Searcher Location: _____

Date Searcher Picked Up: _____

Date Completed: 4-25-02

Searcher Prep & Review Time: 5

Type of Search

NA Sequence (#) _____

AA Sequence (#) _____

Structure (#) (1)

Bibliographic (1)

Litigation _____

Fulltext _____

Vendors and cost where applicable

STN \$127.77

Dialog _____

Questel/Orbit _____

Dr.Link _____

Lexis/Nexis _____

Sequence Systems _____

=> file reg

FILE 'REGISTRY' ENTERED AT 12:07:15 ON 25 APR 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

=> d his

FILE 'REGISTRY' ENTERED AT 11:28:07 ON 25 APR 2002

E CITRIC ACID/CN
L1 1 SEA "CITRIC ACID"/CN
D RN
L2 6536 SEA 77-92-9/CRN
L3 1178 SEA L2 AND M/ELS
L4 99 SEA L2 AND H3N
E ETHYLENE GLYCOL/CN
L5 1 SEA "ETHYLENE GLYCOL"/CN
E SODIUM METABISULFITE/CN
L6 2 SEA "SODIUM METABISULFITE"/CN
L7 1 SEA "SODIUM METABISULFITE (NA2S2O5)"/CN
L8 2 SEA L6 OR L7
E SODIUM DODECYL SULFATE/CN
L9 4 SEA ("SODIUM DODECYL SULFATE"/CN OR "SODIUM DODECYL
SULFATE HEMIHYDRATE"/CN OR "SODIUM DODECYL SULFATE
HYDRATE (8:1)"/CN OR "SODIUM DODECYL SULFATE MONOHYDRATE"
/CN OR "SODIUM DODECYL SULPHATE"/CN)

FILE 'HCA' ENTERED AT 11:34:27 ON 25 APR 2002

L10 74177 SEA L3 OR L4 OR CITRATE#

FILE 'REGISTRY' ENTERED AT 11:34:30 ON 25 APR 2002

SET SMARTSELECT ON
L11 SEL L5 1- CHEM : 23 TERMS
SET SMARTSELECT OFF

FILE 'HCA' ENTERED AT 11:34:31 ON 25 APR 2002

L12 284325 SEA L11

FILE 'REGISTRY' ENTERED AT 11:36:36 ON 25 APR 2002

SET SMARTSELECT ON
L13 SEL L8 1- CHEM : 14 TERMS
SET SMARTSELECT OFF

FILE 'HCA' ENTERED AT 11:36:37 ON 25 APR 2002

L14 2660 SEA L13
L15 2748 SEA NA2S2O5

FILE 'REGISTRY' ENTERED AT 11:37:13 ON 25 APR 2002

SET SMARTSELECT ON
L16 SEL L9 1- CHEM : 185 TERMS
SET SMARTSELECT OFF

FILE 'HCA' ENTERED AT 11:37:16 ON 25 APR 2002

L17 104814 SEA L16
L18 228687 SEA BUFFER?
L19 296471 SEA GLYCOL## OR POLYGLYCOL##
L20 6 SEA L18 AND L19 AND (L14 OR L15) AND L17
L21 6 SEA L18 AND L19 AND (L14 OR L15) AND (L17 OR SDS OR
S(W)D(W)S)
L22 4 SEA L10 AND L12 AND (L14 OR L15) AND (L17 OR SDS OR
S(W)D(W)S)
L23 64545 SEA DIOL# OR POLYDIOL#
L24 106265 SEA (POLYGLYCOL# OR (POLYALKYLENE# OR POLYETHYLENE# OR
POLYPROPYLENE# OR POLYBUTYLENE# OR POLYISOBUTYLENE#) (2A) (GLYCOL# OR OXIDE#) OR (ETHYLENE# OR PROPYLENE# OR BUTYLENE# OR ISOBUTYLENE#) (2A) (POLYOXIDE# OR POLY(W)OXIDE#)) /BI,AB
L25 96483 SEA (POLYOXYALKYLENE# OR POLYOXYETHYLENE# OR POLYOXYPROPYLENE# OR POLYOXYBUTYLENE# OR POLYOXYISOBUTYLENE# OR POLY(W) (GLYCOL# OR OXYALKYLENE# OR OXYETHYLENE# OR OXYPROPYLENE# OR OXYBUTYLENE# OR OXYISOBUTYLENE#)) /BI,AB
L26 34616 SEA (POLYOXY(W) (ALKYLENE# OR ETHYLENE# OR PROPYLENE# OR BUTYLENE# OR ISOBUTYLENE#) OR PEG OR PPG OR PBG OR ALCOX# OR BREOX# OR CARBOWAX# OR EMKAPOL# OR LUTROL# OR MACROGOL# OR PEO OR PLURACOL# OR PLURIOL# OR POLIKOL# OR POLYOX#) /BI,AB
L27 3542 SEA (SUPEROX# OR TENZILIN# OR ADEKA# OR ARCOL# OR EXCENOL# OR LAPROL# OR NIAX# OR PROPYLAN# OR SANNIX# OR VORANOL#) /BI,AB
L28 4 SEA L18 AND (L23 OR L24 OR L25 OR L26) AND (L14 OR L15) AND (L17 OR SDS OR S(W)D(W)S)
L29 5 SEA L10 AND (L23 OR L24 OR L25 OR L26) AND (L14 OR L15) AND (L17 OR SDS OR S(W)D(W)S)
L30 8 SEA L21 OR L22 OR L28 OR L29

FILE 'REGISTRY' ENTERED AT 12:07:15 ON 25 APR 2002

=> file hca

FILE 'HCA' ENTERED AT 12:07:28 ON 25 APR 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

=> d l30 1-8 cbib abs hitstr hitind

L30 ANSWER 1 OF 8 HCA COPYRIGHT 2002 ACS

136:189344 Novel pharmaceutical compositions of antitubercular drugs and process for their preparation. Singh, Amarjit; Jain, Rajesh (Panacea Biotec Limited, India). PCT Int. Appl. WO 2002011728 A2 20020214, 44 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG,


KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-IN89 20010410. PRIORITY: IN 2000-DE720 20000809.

- AB An oral pharmaceutical compn. of antitubercular drugs with enhanced bioavailability comprises Rifampicin and/or isoniazid. Preferably the bioavailability of Rifampicin is enhanced by preventing its degrdn. caused by presence of isoniazid. Rifampicin and/or isoniazid may be present in delayed release and/or extended release form such that minimal amt. of the drug is dissolved at pH 1-4; preferably delayed release of Rifampicin and/or isoniazid is achieved by treating the drugs with pH-sensitive polymers. For example, a bilayer tablet contg. isoniazid in extended release form was prepd. by granulating isoniazid 0.150 g, hydroxypropyl Me cellulose 0.050 g, and iso-Pr alc. 2.000 g (Layer I), and Rifampicin 0.225 g, ethambutol-HCl 0.400 g, pyrazinamide 0.750 g, starch 0.075 g, and water 0.500 g (Layer II). Granulates were dried and compressed into bilayered tablets. Rifampicin (Layer II) was immediately released while isoniazid layer was released in delayed form. Also, an antitubercular formulation in kit form contained (A) one enteric-coated tablet of Rifampicin 150 mg, and (B) one film-coated tablet contg. isoniazid 150 mg, ethambutol-HCl 400 mg, and pyrazinamide 750 mg, or (A) one enteric-coated tablet of isoniazid 150 mg, and (B) one film-coated tablet contg. Rifampicin 225 mg, ethambutol-HCl 400 mg, and pyrazinamide 750 mg.
- IT 151-21-3, Sodium lauryl sulfate
, biological studies 7681-57-4, Sodium metabisulfite
(prepn. of oral tuberculostatic compns. with enhanced bioavailability)
- RN 151-21-3 HCA
- CN Sulfuric acid monododecyl ester sodium salt (8CI, 9CI) (CA INDEX NAME)

$\text{HO}_3\text{SO}^-(\text{CH}_2)_{11}-\text{Me}$

● Na

- RN 7681-57-4 HCA
- CN Disulfurous acid, disodium salt (9CI) (CA INDEX NAME)



2 Na

IC ICM A61K031-496
 ICS A61K031-4409; A61K009-22; A61K009-52
 CC 63-6 (Pharmaceuticals)
 Section cross-reference(s): 1
 IT **Buffers**
 Drug bioavailability
 Gums and Mucilages
 Permeation enhancers
 Polymorphism (crystal)
 Sweetening agents
 Tuberculostatics
 (prepn. of oral tuberculostatic compns. with enhanced bioavailability)
 IT Corn oil
Polyoxyalkylenes, biological studies
 Shellac
 (prepn. of oral tuberculostatic compns. with enhanced bioavailability)
 IT 57-10-3, Palmitic acid, biological studies 57-88-5, Cholesterol, biological studies 63-42-3, Lactose 77-93-0, Triethyl **citrate** 79-41-4D, Methacrylic acid, polymers 100-42-5D, Styrene, copolymers 109-43-3, Dibutyl sebacate 151-21-3, **Sodium lauryl sulfate**, biological studies 557-04-0, Magnesium stearate 7681-57-4, **Sodium metabisulfite** 7758-29-4, Sodium tripolyphosphate 9000-01-5, Acacia gum 9000-30-0, Guar gum 9000-36-6, Karaya gum 9000-65-1, Tragacanth 9002-89-5, Polyvinyl alcohol 9002-96-4, .alpha.-Tocopherol **polyethylene glycol** succinate 9003-39-8, Polyvinylpyrrolidone 9004-34-6, Cellulose, biological studies 9004-38-0, Cellulose acetate phthalate 9004-57-3, Ethyl cellulose 9004-62-0, Hydroxyethyl cellulose 9004-64-2, Hydroxypropyl cellulose 9004-65-3, Hydroxypropyl methyl cellulose 9005-25-8, Starch, biological studies 9005-32-7, Alginic acid 9005-38-3, Sodium alginate 9005-67-8, Tween 60 9012-76-4, Chitosan 9050-31-1, Hydroxypropyl methyl cellulose phthalate 9063-38-1, Sodium starch glycolate 11138-66-2, Xanthan gum 13463-67-7, Titanium dioxide, biological studies 14807-96-6, Talc, biological studies 22839-47-0, Aspartame 25086-15-1, Eudragit L100 25212-88-8, Eudragit L 30D 25322-68-3, **Polyethylene glycol** 31566-31-1, Glyceryl monostearate 45322-29-0, Distearyl

phosphatidylcholine 53237-50-6 54182-62-6, Polacrillin
 57916-92-4, Carbopol 934P 93792-59-7, Hydroxypropyl methyl
 cellulose succinate 106392-12-5, Pluronic F68
 (prepn. of oral tuberculostatic compns. with enhanced
 bioavailability)

L30 ANSWER 2 OF 8 HCA COPYRIGHT 2002 ACS

135:9995 Pharmaceuticals containing sildenafil for treating male
 erectile dysfunction. Vallabhaneni, Ramakrishna Rao (Natco Pharma
 Ltd., India). PCT Int. Appl. WO 2001035926 A2 20010525, 19 pp.
 DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY,
 CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM,
 HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
 LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
 SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW,
 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH,
 CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR,
 NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2.
 APPLICATION: WO 2000-IN105 20001024. PRIORITY: IN 1999-MA1128
 19991118.

AB The invention relates to a novel pharmaceutical compn. contg.
 sildenafil useful for nasal administration in the treatment of male
 erectile dysfunction due to a variety of causes. The compn. is also
 effective in patients with erectile dysfunction due to spinal cord
 injury. The pharmaceutical compn. is in the form of a soln. or a
 colloidal dispersion in a vehicle filled into a specially designed
 dosing device for nasal administration. The invention also provides
 a method for prepg. the compn. contg. sildenafil for nasal
 application for the treatment of male erectile dysfunction. Thus, a
 formulation contained sildenafil **citrate** 10.000,
 PEG-300 30.000, glycerol 20.000, and HCl 10.000% and water
 to 1.0 mL.

IT 151-21-3, Sodium lauryl sulfate
 , biological studies 7681-57-4, Sodium
 metabisulfite
 (pharmaceuticals contg. sildenafil for treating male erectile
 dysfunction)

RN 151-21-3 HCA


CN Sulfuric acid monododecyl ester sodium salt (8CI, 9CI) (CA INDEX
 NAME)

$\text{HO}_3\text{SO}^-(\text{CH}_2)_{11}-\text{Me}$

● Na

RN 7681-57-4 HCA

CN Disulfurous acid, disodium salt (9CI) (CA INDEX NAME)



2 Na

IC ICM A61K009-00
 CC 63-6 (Pharmaceuticals)
 IT **Polyoxyalkylenes**, biological studies
 (ethers; pharmaceuticals contg. sildenafil for treating male
 erectile dysfunction)
 IT Antimicrobial agents
Buffers
 Permeation enhancers
 Solubilizers
 Stabilizing agents
 (pharmaceuticals contg. sildenafil for treating male erectile
 dysfunction)
 IT Bile salts
 Lecithins
Polyoxyalkylenes, biological studies
 (pharmaceuticals contg. sildenafil for treating male erectile
 dysfunction)
 IT 50-81-7, Ascorbic acid, biological studies 56-81-5, Glycerol,
 biological studies 57-11-4, Stearic acid, biological studies
 57-55-6, Propylene **glycol**, biological studies 58-08-2,
 Caffeine, biological studies 59-51-8, Methionine 60-12-8,
 Phenylethyl alcohol 62-38-4, Phenylmercuric acetate 64-17-5,
 Ethanol, biological studies 64-19-7, Acetic acid, biological
 studies 77-92-9, Citric acid, biological studies 98-92-0,
 Nicotinamide 100-51-6, Benzyl alcohol, biological studies
 111-90-0, Diethylene **glycol** monoethyl ether 121-33-5,
 Vanillin 121-54-0, Benzethonium chloride 127-09-3, Sodium
 acetate 134-03-2, Sodium ascorbate 139-33-3, disodium EDTA
 151-21-3, **Sodium lauryl sulfate**
 , biological studies 577-11-7, Docusate sodium 872-50-4,
 N-Methyl-2-pyrrolidone, biological studies 1310-73-2, Sodium
 hydroxide (NaOH), biological studies 7558-79-4, Disodium
 hydrogen phosphate 7631-90-5, Sodium bisulfite 7647-01-0,
 Hydrochloric acid, biological studies 7664-38-2, Phosphoric acid,
 biological studies **7681-57-4, Sodium**
metabisulfite 7778-77-0, Potassium dihydrogen phosphate
 8044-71-1, Cetrinide 9002-89-5, Poly(vinyl alcohol) 9003-01-4,
 Poly(acrylic acid) 9003-39-8, PVP 9004-32-4, Carboxymethyl
 cellulose sodium salt 9004-62-0, Hydroxyethyl cellulose
 9004-64-2, Hydroxypropyl cellulose 9004-65-3, HPMC 9036-19-5,
 Octoxynol 12619-70-4, Cyclodextrin 25322-68-3,
Polyethylene glycol 27194-74-7, Propylene

glycol monolaurate 31566-31-1, Glyceryl monostearate
 67167-59-3, Polyethylene glycol stearate
 106392-12-5, Poloxamer 139755-83-2, Sildenafil 171599-83-0,
 Sildenafil **citrate** 252920-86-8 252951-59-0
 252959-28-7 255885-45-1 255885-46-2 255885-47-3 255885-48-4
 255885-49-5 255885-50-8 340963-09-9
 (pharmaceuticals contg. sildenafil for treating male erectile
 dysfunction)

L30 ANSWER 3 OF 8 HCA COPYRIGHT 2002 ACS


134:46821 Pharmaceutical formulations containing morphine for intranasal
 administration. Achari, Raja G.; Behl, Charanjit R.; Demeireles,
 Jorge C.; Dua, Ramneik; Romeo, Vincent D.; Sileno, Anthony P.
 (Nastech Pharmaceutical Co., Inc., USA). PCT Int. Appl. WO
 2000076506 A1 20001221, 57 pp. DESIGNATED STATES: W: AE, AG, AL,
 AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK,
 DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,
 KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,
 MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
 TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU,
 TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI,
 FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG.
 (English). CODEN: PIXXD2. APPLICATION: WO 2000-US14157 20000523.
 PRIORITY: US 1999-334537 19990616.

AB The present invention relates to a pharmaceutical formulation for
 intranasal administration comprising morphine or pharmaceutically
 acceptable salt at pH values 3.0-7.0. Such formulations provide
 enhanced absorption of morphine or pharmaceutically acceptable
 salts. In one embodiment, the present invention provides a method
 for eliciting an analgesic or anesthetic response in a mammal which
 includes nasally administering a therapeutically effective amt. of
 morphine or pharmaceutically acceptable salt at pH 3.0-7.0. Thus, a
 formulation contained morphine sulfate 5.0, sodium **citrate**
 dihydrate 0.30, sodium salicylate 1.0, glycerin 5.0, **sodium**
metabisulfite 0.10, and water to 100%.

IT 6132-04-3, Sodium **citrate** dihydrate
 (buffer; pharmaceutical formulations contg. morphine
 for intranasal administration)

RN 6132-04-3 HCA


CN 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, trisodium salt,
 dihydrate (9CI) (CA INDEX NAME)



●3 Na

●2 H₂O

IT 151-21-3, SLS, biological studies
 (pharmaceutical formulations contg. morphine for intranasal
 administration)
 RN 151-21-3 HCA
 CN Sulfuric acid monododecyl ester sodium salt (8CI, 9CI) (CA INDEX
 NAME)



● Na

IC ICM A61K031-44
 ICS A61F013-00
 CC 63-6 (Pharmaceuticals)
 IT Prolamins
 (carbonate, **buffer**; pharmaceutical formulations contg.
 morphine for intranasal administration)
 IT 64-19-7, Acetic acid, biological studies 102-71-6, Trolamine,
 biological studies **6132-04-3**, Sodium **citrate**
 dihydrate 14265-44-2, Phosphate, biological studies
 (**buffer**; pharmaceutical formulations contg. morphine
 for intranasal administration)
 IT 50-70-4, Sorbitol, biological studies 54-21-7, Sodium salicylate
 56-81-5, Glycerol, biological studies 57-55-6, Propylene
glycol, biological studies 112-80-1, Oleic acid,
 biological studies 139-33-3, Disodium edetate **151-21-3**,
SLS, biological studies 9000-01-5, Acacia gum 9002-89-5,
 Poly(vinyl alcohol) 9004-32-4, Carboxymethyl cellulose
 9004-64-2, Hydroxypropyl cellulose 9004-67-5, Methyl cellulose
 9004-99-3, **Polyethylene glycol** stearate

9005-32-7, Alginic acid 9005-64-5, Tween 20 9012-76-4, Chitosan
 9036-19-5, Octoxynol 11138-66-2, Xanthan gum 25496-72-4,
 Glyceryl monooleate
 (pharmaceutical formulations contg. morphine for intranasal
 administration)

L30 ANSWER 4 OF 8 HCA COPYRIGHT 2002 ACS

133:198661 Seeded microcapsules for use in tablets, pharmaceutical
 agents and nutritional compounds. Redding, Bruce K., Jr.; Harden,
 Jerome (Verion Inc., USA). U.S. US 6110501 A 20000829, 14 pp.,
 Cont. of U.S. Ser. No. 111,897. (English). CODEN: USXXAM.
 APPLICATION: US 1999-226356 19990106. PRIORITY: US 1993-137439
 19931108; US 1995-576636 19951221; US 1997-908232 19970807; US
 1998-PV82165 19980417; US 1998-111897 19980708.


AB Disclosed is a microcapsule having a core, a shell and seeds fully
 or partially embedded in said shell. The core and seeds are active
 substances which preferably function as a leavening agent. The
 shell is composed of either a water sol. or meltable natural
 polymer, including vegetable waxes. When the shell is ruptured, the
 active substances will react with each other and the dough mixt.
 thereby producing a leavening effect and/or dough conditioning
 effect in baked goods. Seeded vitamin C microcapsules were made by
 mixing ascorbic acid 700 g with molten cottonseed vegetable wax 250,
 and microcryst. cellulose 50 g.

IT 68-04-2, Sodium Citrate 151-21-3,
 Sodium Lauryl Sulfate, biological
 studies 866-83-1, Potassium Citrate
 7681-57-4, Sodium Metabisulfite

(seeding material for microcapsules for use in tablets contg.
 pharmaceutical agents and nutritional compds.)

RN 68-04-2 HCA


CN 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, trisodium salt (9CI)
 (CA INDEX NAME)



●3 Na


RN 151-21-3 HCA

CN Sulfuric acid monododecyl ester sodium salt (8CI, 9CI) (CA INDEX
 NAME)




● Na

RN 866-83-1 HCA
 CN 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, monopotassium salt
 (9CI) (CA INDEX NAME)



● K

RN 7681-57-4 HCA
 CN Disulfurous acid, disodium salt (9CI) (CA INDEX NAME)



2 Na

IC ICM A61K009-50
 ICS A61K009-51
 NCL 424490000
 CC 63-6 (Pharmaceuticals)
 Section cross-reference(s): 18
 IT Ethers, biological studies
 (polyoxyethylene; seeding material for microcapsules
 for use in tablets contg. pharmaceutical agents and nutritional
 compds.)
 IT Alcohols, biological studies
 Bentonite, biological studies
 Carbohydrates, biological studies
 Carnauba wax
 Corn oil

Cottonseed oil
 Gelatins, biological studies
 Kaolin, biological studies
 Lanolin
 Lecithins
 Paraffin oils
 Peanut oil
 Petrolatum
 Polyoxyalkylenes, biological studies
 Shellac
 Zeins

(seeding material for microcapsules for use in tablets contg. pharmaceutical agents and nutritional compds.)

IT 50-70-4, Sorbitol, biological studies 50-99-7, Dextrose, biological studies 54-64-8 55-56-1, Chlorhexidine 55-68-5, Phenylmercuric Nitrate 56-81-5, Glycerin, biological studies 57-11-4, Stearic Acid, biological studies 57-15-8, Chlorobutanol 57-50-1, Sucrose, biological studies 57-55-6, Propylene Glycol, biological studies 57-88-5, Cholesterol, biological studies 60-00-4, Edetic Acid, biological studies 60-12-8, Phenylethyl Alcohol 62-38-4, Phenylmercuric Acetate 63-42-3, Lactose 65-85-0, Benzoic Acid, biological studies 67-63-0, Isopropyl Alcohol, biological studies 68-04-2, Sodium Citrate 69-65-8, Mannitol 74-98-6, Propane, biological studies 75-28-5, Isobutane 75-69-4, Trichloromonofluoromethane 75-71-8, Dichlorodifluoromethane 79-14-1, biological studies 79-41-4D, Methacrylic acid, polymers 81-07-2, Saccharin 84-66-2, Diethyl Phthalate 87-99-0, Xylitol 94-13-3, Propylparaben 94-26-8, Butylparaben 99-76-3, Methylparaben 100-51-6, Benzyl Alcohol, biological studies 102-71-6, Triethanolamine, biological studies 102-98-7, Phenylmercuric Borate 106-97-8, Butane, biological studies 110-17-8, Fumaric Acid, biological studies 110-27-0, Isopropyl Myristate 110-44-1, Sorbic Acid 111-42-2, Diethanolamine, biological studies 111-62-6, Ethyl Oleate 112-92-5, Stearyl Alcohol 120-47-8, Ethylparaben 124-38-9, Carbon dioxide, biological studies 128-37-0, Butylated Hydroxytoluene, biological studies 128-44-9, Saccharin Sodium 134-03-2, Sodium Ascorbate 141-43-5, Monoethanolamine, biological studies 142-91-6, Isopropyl Palmitate 144-55-8, Sodium Bicarbonate, biological studies 151-21-3, Sodium Lauryl Sulfate, biological studies 532-32-1, Sodium Benzoate 557-04-0, Magnesium Stearate 557-05-1, Zinc Stearate 577-11-7, Docusate Sodium 866-83-1, Potassium Citrate 1320-37-2, Dichlorotetrafluoroethane 1327-43-1, Magnesium Aluminum silicate 1338-41-6D, Sorbitans, esters 1592-23-0, Calcium Stearate 6915-15-7, Malic Acid 7631-86-9, Colloidal Silicon Dioxide, biological studies 7647-01-0, Hydrochloric Acid, biological studies 7647-14-5, Sodium Chloride, biological studies 7681-57-4, Sodium Metabisulfite 7758-87-4, Tribasic Calcium Phosphate 7778-18-9, Calcium Sulfate 8044-71-1, Cetrimide 9000-30-0, Guar Gum 9000-65-1, Tragacanth

9002-89-5, Polyvinyl Alcohol 9003-39-8, Povidone 9004-32-4, Carboxymethylcellulose Sodium 9004-34-6, Cellulose, biological studies 9004-38-0, Cellulose Acetate Phthalate 9004-53-9, Dextrin 9004-57-3, Ethylcellulose 9004-62-0, Hydroxyethyl Cellulose 9004-64-2, Hydroxypropyl Cellulose 9004-65-3, HydroxypropylMethylcellulose 9004-67-5, Methylcellulose 9004-99-3, **Polyoxyethylene** Stearate 9005-25-8, Starch, biological studies 9005-32-7, Alginic Acid 9005-37-2, Propylene Glycol Alginate 9050-04-8 9050-31-1, HydroxypropylMethylcellulose Phthalate 10103-46-5, Calcium Phosphate 13463-67-7, Titanium Dioxide, biological studies 14807-96-6, Talc, biological studies 24634-61-5, Potassium Sorbate 25013-16-5, Butylated Hydroxyanisole 25322-68-3, **Polyethylene Glycol** 31566-31-1, Glyceryl Monostearate 31692-85-0, Glycofurol 36653-82-4, Cetyl Alcohol 54182-62-6D, Polacrilin, potassium form 62212-91-3, Sodium Starch 106392-12-5, Poloxamer
(seeding material for microcapsules for use in tablets contg. pharmaceutical agents and nutritional compds.)

L30 ANSWER 5 OF 8 HCA COPYRIGHT 2002 ACS


133:94512 Improved formulation for topical non-invasive application in vivo. Cevc, Gregor (Idea Innovative Dermale Applikationen G.m.b.H., Germany). PCT Int. Appl. WO 2000038653 A1 20000706, 73 pp.
DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG.
(English). CODEN: PIXXD2. APPLICATION: WO 1998-EP8421 19981223.

AB A formulation comprises mol. arrangements capable of penetrating pores in a barrier, owing to penetrant adaptability, despite the fact that the av. diam. of the pores is smaller than the av. penetrant diam., provided that the penetrants can transport agents or cause permeation through the pores after penetrants have entered pores. The formulation comprises at least 1 consistency builder in an amt. that increases the formulation to maximally 5 Nm/s so that spreading over is enabled. The formulation also contains 1 antioxidant in an amt. that reduces the increase of oxidn. index to <100% per 6 mo and/or at least 1 microbicide in an amt. that reduces the bacterial count of 1 million germs added/g of total mass of the formulation to <100 in the case of aerobic bacteria, to <10 in the case of entero-bacteria, and to <1 in the case of Pseudomonas aeruginosa or Staphylococcus aureus, after a period of 4 days. Thus, a compn. contained soybean phosphatidylcholine 347, Tween-80 623, **sodium dodecyl sulfate** 30, benzyl alc. 50, clobetasol 17-propionate 25 and pH 6.5 50 mM phosphate buffer 9000 mg.

IT 7681-57-4, **Sodium metabisulfit**

(penetrating formulation for topical non-invasive application in

vivo)
 RN 7681-57-4 HCA
 CN Disulfurous acid, disodium salt (9CI) (CA INDEX NAME)



2 Na

IC ICM A61K009-127
 CC 63-6 (Pharmaceuticals)
 Section cross-reference(s): 1
 IT Amines, biological studies
 Betaines
 Ceramides
 Cerebrosides
 Collagens, biological studies
 Fatty acids, biological studies
 Gangliosides
 Gelatins, biological studies
 Glycolipids
 Glycosides
 Lipids, biological studies
 Lysophospholipids
 Phenols, biological studies
 Phosphatidic acids
 Phosphatidylcholines, biological studies
 Phosphatidylethanolamines, biological studies
 Phosphatidylglycerols
 Phosphatidylinositols
 Phosphatidylserines
 Phospholipids, biological studies
 Plasmalogens
 Polymers, biological studies
Polyoxyalkylenes, biological studies
 Polysiloxanes, biological studies
 Sphingomyelins
 Sphingosines
 Sulfatides
 Tocopherols
 (penetrating formulation for topical non-invasive application in vivo)
 IT **Polyoxyalkylenes**, biological studies
Polyoxyalkylenes, biological studies
 (polyester-; penetrating formulation for topical non-invasive application in vivo)
 IT Polyesters, biological studies

Polyesters, biological studies

(polyoxyalkylene-; penetrating formulation for topical
non-invasive application in vivo)

IT 50-06-6, Phenobarbital, biological studies 50-33-9,
Phenylbutazone, biological studies 50-78-2, Acetylsalicylic acid
50-81-7, Ascorbic Acid, biological studies 50-99-7, Glucose,
biological studies 52-67-5, Penicillamine 53-86-1, Indomethacin
54-05-7, Chloroquine 54-64-8, Thiomersal 55-56-1, Chlorhexidine
55-68-5, Phenylmercuric nitrate 56-81-5, Glycerol, biological
studies 57-15-8, Chlorbutanol 59-02-9, .alpha.-Tocopherol
59-05-2, Methotrexate 59-50-7, 4-Chloro-m-cresol 60-00-4, EDTA,
biological studies 61-68-7, Mefenamic acid 62-38-4,
Phenylmercuric acetate 62-56-6, Thiourea, biological studies
64-17-5, Ethyl alcohol, biological studies 65-85-0, Benzoic acid,
biological studies 67-63-0, Isopropyl alcohol, biological studies
67-68-5D, DMSO, alkyl derivs. 69-72-7, Salicylic Acid, biological
studies 69-93-2, Uric acid, biological studies 70-18-8,
Glutathione, biological studies 70-30-4, Hexachlorophene
81-24-3D, salts 81-25-4D, salts 83-44-3D, salts 83-89-6,
Quinacrine 86-74-8, Carbazole 89-65-6 90-05-1, Guaiacol
90-34-6, Primaquine 94-13-3, Propylparaben 94-18-8,
Benzylparaben 94-26-8, Butylparaben 97-23-4, Dichlorophene
99-50-3, Protocatechuic Acid 99-76-3, Methylparaben 100-51-6,
Benzyl alcohol, biological studies 102-98-7, Phenylmercuric borate
103-90-2, Acetaminophen 107-15-3D, Ethylenediamine, derivs.
107-21-1, Ethylene glycol, biological studies 110-27-0,
Isopropyl myristate 110-44-1, Sorbic acid 112-53-8, 1-Dodecanol
112-80-1, Oleic acid, biological studies 118-42-3,
Hydroxychloroquine 119-13-1, .delta.-Tocopherol 120-47-8,
Ethylparaben 121-33-5, Vanillin 121-79-9, Propyl Gallate
122-39-4, Diphenylamine, biological studies 123-03-5,
Cetylpyridinium chloride 123-31-9, Hydroquinone, biological
studies 128-37-0, BHT, biological studies 129-20-4,
Oxyphenbutazone 137-66-6 138-14-7, Desferal 141-78-6, EtOAc,
biological studies 143-19-1, Sodium oleate 143-28-2, Oleyl
alcohol 148-03-8, .beta.-Tocopherol 149-91-7, Gallic Acid,
biological studies 151-41-7, Lauryl sulfate 302-95-4, Sodium
deoxycholate 327-97-9, Chlorogenic acid 331-39-5, Caffeic acid
360-65-6D, salts 446-86-6, Azathioprine 475-31-0D, salts
476-66-4, Ellagic Acid 484-78-6, 3-Hydroxykynurenine 490-79-9,
Gentisic acid 500-38-9, Nordihydroguaiaretic Acid 516-50-7D,
salts 525-66-6, Propranolol 530-57-4, Syringic Acid 530-59-6,
Sinapic acid 530-78-9, Flufenamic acid 534-61-2, IsoChlorogenic
acid 538-71-6, Phenododecinium bromide 548-93-6,
3-Hydroxyanthranilic acid 616-91-1, N-Acetylcysteine 621-82-9,
Cinnamic acid, biological studies 629-25-4, Sodium laurate
635-65-4, Bilirubin, biological studies 822-17-3, Sodium linoleate
1118-68-9D, Dimethylglycine, alkyl derivs. 1135-24-6, Ferulic acid
1319-77-3, Cresol 1643-20-5, Dodecyldimethylamine oxide
1948-33-0, tert-Butylhydroquinone 1951-25-3, Amiodarone
2002-22-4D, derivs. 2495-84-3 3650-09-7, Carnosic acid
4353-06-4 5432-30-4 5677-55-4, Ubiquinol-10 5957-80-2,

Carnosol 7235-40-7, .beta.-Carotene 7347-25-3, Sodium taurate
 7616-22-0, .gamma.-Tocopherol 7631-90-5, Sodium bisulphite
7681-57-4, Sodium metabisulfite
 7747-53-7 9000-07-1, Carrageenan 9000-30-0, Guar-gum
 9000-65-1, Tragacanth 9000-69-5, Pectin 9001-05-2, Catalase
 9002-88-4, Polyethylene 9002-89-5, Polyvinyl alcohol 9002-92-0,
Polyethylene glycol dodecyl ether 9002-96-4
 9003-39-8, Polyvinylpyrrolidone 9004-32-4, Carboxymethyl cellulose
 sodium salt 9004-34-6D, Cellulose, derivs., biological studies
 9004-61-9, Hyaluronic Acid 9004-62-0, Hydroxyethyl cellulose
 9004-64-2, Hydroxypropyl cellulose 9004-65-3, Hydroxypropylmethyl
 cellulose 9004-67-5, Methyl cellulose 9004-98-2,
Polyethylene glycol oleyl ether 9004-99-3, Myrj
 45 9005-32-7, Alginic acid 9005-64-5, Tween 20 9005-65-6,
 Tween 80 9012-36-6, Agarose 9012-76-4, Chitosan 9013-66-5,
 Glutathione peroxidase 9036-19-5, **Polyethylene**
glycol octylphenyl ether 9043-30-5, **Polyethylene**
glycol isotridecyl ether 9054-89-1, Superoxide dismutase
 9086-85-5, Poly(hydroxypropyl) methacrylate 10540-29-1, Tamoxifen
 11138-66-2, Xanthan 12041-76-8, Dichlorobenzylalcohol
 15307-86-5, Diclofenac 15687-27-1, Ibuprofen 16409-34-0, Sodium
 glycodeoxycholate 16690-40-7 18175-45-6, Sodium elaidate
 18472-51-0, Chlorhexidine gluconate 18683-91-5, Ambroxol
 19767-45-4, Mesna 20283-92-5, Rosmarinic acid 20902-45-8,
 Penicillamine disulfide 21829-25-4, Nifedipine 22071-15-4,
 Ketoprofen 22204-53-1, Naproxen 22494-42-4, Diflunisal
 23288-49-5, Probuco1 25013-16-5, BHA 25014-41-9,
 Polyacrylonitrile 25249-16-5 25322-68-3, **PEG**
 25429-38-3, Coumaric acid 25655-41-8, Povidone-iodine
 26570-48-9, **Polyethylene glycol**-diacrylate
 26746-38-3, Di-tert-butylphenol 27306-76-9, **Polyethylene**
glycol cetyl stearyl ether 27306-79-2,
Polyethylene glycol myristyl ether 29122-68-7,
 Atenolol 29349-22-2, Chlorobenzyl alcohol 33425-76-2
 36322-90-4, Piroxicam 36413-60-2, Quinic Acid 37640-71-4,
 Aprindine 53188-07-1, Trolox 53584-19-3 55985-32-5,
 Nicardipine 59227-89-3, Azone 63675-72-9, Nisoldipine
 66085-59-4, Nimodipine 68047-06-3, Hydroxytamoxifen 68555-46-4
 75530-68-6, Nilvadipine 77400-65-8, Asocainol 85261-20-7,
 Decanoyl N-methylglucamide 87246-72-8 88306-53-0 90522-12-6
 91729-95-2, Rosmaridiphenol 99716-88-8, Methallylsulfonic acid
 homopolymer 106392-12-5, Poloxamer 110101-67-2, U74006F
 118457-14-0, Nebivolol 121869-32-7 148081-72-5,
 1-O-Hexyl-2,3,5-trimethylhydroquinone
 (penetrating formulation for topical non-invasive application in
 vivo)

L30 ANSWER 6 OF 8 HCA COPYRIGHT 2002 ACS

131:204596 Antituberculosis pharmaceutical composition containing
 rifampicin, isonizide pyrazinamide and ethambutol. Kshirsagar,
 Rajesh Suresh (Lupin Laboratories Ltd., India). Belg. BE 1010972 A6
 19990302, 38 pp. (French). CODEN: BEXXAL. APPLICATION: BE

1997-554 19970627. PRIORITY: IN 1996-BO499 19961009; IN 1996-BO500 19961009.

AB The title pharmaceutical compns. are claimed. Tablets were prepd. form rifampicin 450, ethambutol hydrochloride 800, pyrazinamide 1500, isonizide 300, microcryst. cellulose 585, ascorbic acid 9, **sodium lauryl sulfate** 15, starch 150, crospovidone 165, silicone dioxide 18, talc 39, and magnesium stearate 39 g. The tablets were coated with a mixt. contg. Tabcoat TC-MB 176.25, and ferric oxide 30. Stability of the tablets were studied.

IT 151-21-3, **Sodium lauryl sulfate**
, biological studies 7681-57-4, **Sodium metabisulfite**

(antituberculosis pharmaceutical compn. contg. rifampicin, isonizide pyrazinamide and ethambutol)

RN 151-21-3 HCA


CN Sulfuric acid monododecyl ester sodium salt (8CI, 9CI) (CA INDEX NAME)

$\text{HO}_3\text{SO}^-(\text{CH}_2)_{11}-\text{Me}$

● Na

RN 7681-57-4 HCA

CN Disulfurous acid, disodium salt (9CI) (CA INDEX NAME)



2 Na

IC ICM A61K009-20

ICS A61K031-00

CC 63-6 (Pharmaceuticals)

IT Acrylic polymers, biological studies

Carbohydrates, biological studies

Carnauba wax

Castor oil

Gelatins, biological studies

Lanolin

Paraffin oils

Polyoxyalkylenes, biological studies

Zeins

(antituberculosis pharmaceutical compn. contg. rifampicin, isonizide pyrazinamide and ethambutol)


IT 50-70-4, Sorbitol, biological studies 50-81-7, L-Ascorbic acid, biological studies 54-85-3, Isonizide 56-81-5, 1,2,3-Propanetriol, biological studies 57-15-8, Chlorobutanol 57-55-6, 1,2-Propanediol, biological studies 69-65-8, Mannitol 77-93-0, Triethyl **citrate** 79-10-7D, Acrylic acid, polymers 98-96-4, Pyrazinamide 102-76-1, Triacetin 109-43-3, Dibutylsebacate 110-17-8, 2-Butenedioic acid (2E)-, biological studies 121-79-9, Propyl gallate 128-37-0, biological studies 134-03-2, Sodium ascorbate **151-21-3, Sodium lauryl sulfate**, biological studies 471-34-1, Calciumcarbonate, biological studies 557-04-0, Magnesium stearate 577-11-7, Sodium docusate 1070-11-7, Ethambutol hydrochloride 1309-37-1, Iron oxide (Fe2O3), biological studies 1309-48-4, Magnesium oxide, biological studies 1335-30-4, Aluminum silicate 1343-88-0, Magnesium silicate 7439-95-4, Magnesium, biological studies 7631-86-9, Silicon dioxide, biological studies **7681-57-4, Sodium metabisulfite** 7757-93-9, Dicalcium phosphate 7758-87-4, Tricalcium phosphate 7778-18-9, Calcium sulfate 9000-30-0, Guar gum 9002-89-5, Polyvinyl alcohol 9003-39-8, Povidone 9004-32-4, Sodium carboxymethyl cellulose 9004-38-0, Cellulose phthalate acetate 9004-53-9, Dextrin 9004-54-0, Dextran, biological studies 9004-57-3, Ethyl cellulose 9004-62-0, Hydroxyethyl cellulose 9004-64-2, Hydroxypropyl cellulose 9004-67-5, Methyl cellulose 9005-25-8, Starch, biological studies 9005-32-7, Alginic acid 9005-38-3, Sodium alginate 9005-65-6, Polysorbate 80 13292-46-1, Rifampicin 13463-67-7, Titanium oxide (TiO2), biological studies 25013-16-5, Butylhydroxyanisole 25087-26-7, Polymethacrylic acid 25322-68-3 25496-72-4, Glyceryl monooleate 36653-82-4, Hexadecyl alcohol

(antituberculosis pharmaceutical compn. contg. rifampicin, isonizide pyrazinamide and ethambutol)

L30 ANSWER 7 OF 8 HCA COPYRIGHT 2002 ACS

109:107386 3-Methoxy-4-hydroxyphenylglycol fluorescence-polarization immunoassay, components for preparing and carrying out the assay, and methods for preparing them. Zeitvogel, Christine Helene; Betebenner, David Allen; Adamczyk, Maciej Bogdan; Vaughan, Kenward Shaw (Abbott Laboratories, USA). Eur. Pat. Appl. EP 252405 A2 19880113, 25 pp. DESIGNATED STATES: R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL. (English). CODEN: EPXXDW. APPLICATION: EP 1987-109356 19870630. PRIORITY: US 1986-883898 19860709.

GI




AB A fluorescence-polarization immunoassay for quantitating levels of the norepinephrine metabolite 3-methoxy-4-hydroxyphenylglycol (MHPG) in biol. fluids, tracers and immunogens based on methoxybenzene derivs. I [R1 = OR4, F, Br, Cl, I, OPO3H, OPO3R4, OSO2R4, Q1, RZQ; R2 = H when R1 = RZQ, RZQ when R1 .noteq. RZQ; R3 = H, OH, Me, Et; R4 = R5R6; R5 = linking group with .ltoreq.7 heteroatoms and 0-20 C atoms arranged in straight or branched chain with .ltoreq.2 rings; R6 = H, CO, NH; when Q = polyamino acid (deriv.) or immunol. active carrier, Z = N, NH, SO2, PO2, PSO, or glucuronide and R = R5; when Q = fluorescein (deriv.), Z = CO, NH, CH2NH, or CS and R = linking group with .ltoreq.10 heteroatoms and 0-20 C atoms arranged in straight or branched chain with .ltoreq.2 rings] and antibodies for use in the assay, and methods to prep. these components are disclosed. The assay is characterized by use of a novel stabilizing matrix for the fluorescent tracers and by an improved specimen prepn. method using a Mg silicate resin for redn. of specimen background and interfering metabolites. A std. curve for MHPG concn. was prepd. using N-[4-[5-(1,2-dihydroxyethane)-2-hydroxy-3-methoxyphenyl]-2-butenoyl]-4'-aminomethylfluorescein (prepn. described) as tracer and antiserum prepd. by immunizing rabbits with 4-[5-(1,2-dihydroxyethane)-2-hydroxy-3-methoxyphenyl]-2-butenic acid coupled to bovine serum albumin or keyhole limpet hemocyanin. Both the tracer and immunogen were prepd. from acetovanillone. Each MHPG calibrator in artificial urine was incubated for 3 h at 56.degree. with acetate **buffer** and glucuronidase. Mg silicate resin was added, followed by 80%-satd. NaCl-3M HCl, and the sample was vortexed for 1 min and centrifuged. The supernatant was mixed with antiserum and **SDS** in 0.05M Tris at pH 7.5 and 0.1% NaN3, and after 4 min, a fluorescent sample background reading was taken. The remaining supernatant, antiserum, and tracer [in a stabilizer matrix of DMSO 25%, ethylene **glycol** 75% (vol./vol.), NaCl 1%, **Na2S2O5** 0.1%, and NaN3 0.1%] were incubated and a final reading was taken.

IT 7681-57-4, **Sodium metabisulfite**

(tracer stabilization in matrix contg., for methoxyhydroxyphenylglycol fluorescence-polarization immunoassay)

RN 7681-57-4 HCA

CN Disulfurous acid, disodium salt (9CI) (CA INDEX NAME)



2 Na

- IC ICM C07D493-10
ICS G01N033-533; G01N033-542; G01N033-68; C07C049-84; C07C049-86;
C07C069-738; C07C069-734; C07C059-64; C07C059-90; C07D307-46
- ICI C07D493-10, C07D311-00, C07D307-00
- CC 9-5 (Biochemical Methods)
Section cross-reference(s): 25
- IT 26628-22-8, Sodium azide 67-68-5, Dimethyl sulfoxide, uses and
miscellaneous 107-21-1, Ethylene glycol, uses and
miscellaneous 7647-14-5, Sodium chloride, uses and miscellaneous
7681-57-4, Sodium metabisulfite
(tracer stabilization in matrix contg., for
methoxyhydroxyphenylglycol fluorescence-polarization immunoassay)
- L30 ANSWER 8 OF 8 HCA COPYRIGHT 2002 ACS
- 105:2984 A versatile transition metal salt reaction for a wide range of
common biochemical reagents: an instantaneous and quantifiable
color test. Fleming, Nigel; Nixon, Ralph A. (Mailman Res. Cent.,
McLean Hosp., Belmont, MA, 02178, USA). Anal. Biochem., 154(2),
691-701 (English) 1986. CODEN: ANBCA2. ISSN: 0003-2697.
- AB A rapid and sensitive spot test amenable to visual or
spectrophotometric quantitation was developed for a wide variety of
biochem. reagents by utilizing CuCl₂ and its large no. of related
colored compds. This assay is potentially a widely applicable
multipurpose test for rapidly detecting the presence of unknown
substances. Combination of the test sample with the working reagent
results in the immediate formation of a distinctive colored product
that can be precipitable. Some compds. require the further addn. of
NaOH to generate the distinctively colored product. Distinctive
reactions occur with the following reagents, and their limit of
visual detection is indicated in parentheses: NH₄HCO₃ (12.5 mM),
NH₄OAc (25 mM), NH₄OH (0.1%), (NH₄)₂SO₄ (2%), (NH₄)₂SO₈ (0.02 mM),
L-(+)-cysteine (0.07 mM), dithiothreitol (DTT) (1.25 mM), EDTA (0.6
mM), ethylene glycol bis(.beta.-aminoethyl ether)
N,N'-tetraacetic acid (5 mM), D-glucose (6 mM), glycerol (0.3%),
imidazole (12.5 mM), DL-methionine (100 mM), mercaptoethanol
(0.05%), NaN₃ (19 mM, 0.1%), Na dithionite (0.25%), Na metabisulfite
(25 mM), NaNO₂ (6.2 mM), Na periodate (3.1 mM), Na₂SO₃ (12.5 mM), Na
thiosulfate (12.5 mM), sucrose (6 mM), and N,N,N',N'-
tetramethylethylenediamine (0.05%). A distinctive exothermic
reaction occurs with H₂O₂, but without color change. Compds.
reacting insignificantly include 50 mM Tris buffer, urea,


N,N'-methylenebisacrylamide, **SDS**, iso-PrOH, NaF, TCA, PhOH, mannose, K₂HPO₄, guanidine HCl, chloramine-T, MgCl₂, and boric acid, where the solids were tested at approx. 10 mg/mL. Spectrophotometric std. curves were developed for DTT and NaN₃ utilizing the clear supernatants resulting from these reactions. Combinations of at least 4 reagents could be discriminated, as demonstrated with mixts. of glucose, NaN₃, EDTA, and DTT. In addn., (NH₄)₂SO₄ could be detected to a limit of 4% in the presence of protein, DTT, and EDTA in a 50 mM Tris **buffer**. Spot tests were developed which utilized reagent-impregnated filter paper and gave distinctive colored products on addn. of 5 .mu.L of test sample.

IT 7681-57-4

(detection of, by color reaction with copper chloride, biochem. anal. in relation to)

RN 7681-57-4 HCA

CN Disulfurous acid, disodium salt (9CI) (CA INDEX NAME)



2 Na

CC 9-5 (Biochemical Methods)

Section cross-reference(s): 79, 80

IT 50-99-7, analysis 52-90-4, analysis 56-81-5, analysis 57-50-1, analysis 59-51-8 60-00-4, analysis 60-24-2 67-42-5 110-18-9 288-32-4, analysis 631-61-8 1066-33-7 1336-21-6 3483-12-3 7632-00-0 **7681-57-4** 7727-54-0 7757-83-7 7772-98-7 7775-14-6 7783-20-2, analysis 7790-28-5 26628-22-8 (detection of, by color reaction with copper chloride, biochem. anal. in relation to)

```

                E UTERMOHLEN JOSEPH/AU
L2              14 S E3-E5
L3              0 S L2 AND (BISULFITE OR METABISULFITE)
L4              1 S L2 AND ETHYLENE GLYCOL
L5             19135 S BISULFITE OR METABISULFITE
L6             100 S L5 AND (SDS OR SODIUM DODECYL)
L7              6 S L6 AND GLYCOL
L8              0 S L7 AND CITRATE
L9              5 S L7 AND BUFFER
L10             1 S L7 NOT L9
L11            1182 S DEPARAFFINIZ?
L12             3 S L11 AND (BISULFITE OR METABISULFITE)
L13            4572 S CELL CONDITION?
L14             0 S L13 AND (BISULFITE OR METABISULFITE)
L15            145 S CONDITION? SOLUTION?
L16             2 S L15 AND (BISULFITE OR METABISULFITE)
L17            1344 S ANTIGEN RETRIEVAL
L18             0 S L17 AND (BISULFITE OR METABISULFITE)
L19            6917 S EMBEDD? AND (REMOV? OR ETCH?)
L20             9 S L19 AND (BISULFITE OR METABISULFITE)
L21            25 S L6 AND CELL?
L22            20 DUP REMOV L21 (5 DUPLICATES REMOVED)

```

=> s 16 and citrate

```
L23            0 L6 AND CITRATE
```

=> d his

(FILE 'HOME' ENTERED AT 10:32:27 ON 25 APR 2002)

FILE 'CAPLUS, CAOLD, MEDLINE, BIOSIS' ENTERED AT 10:33:10 ON 25 APR 2002

```

                E TOWNE PENNY/AU
L1              2 S E1
                E UTERMOHLEN JOSEPH/AU
L2              14 S E3-E5
L3              0 S L2 AND (BISULFITE OR METABISULFITE)
L4              1 S L2 AND ETHYLENE GLYCOL
L5             19135 S BISULFITE OR METABISULFITE
L6             100 S L5 AND (SDS OR SODIUM DODECYL)
L7              6 S L6 AND GLYCOL
L8              0 S L7 AND CITRATE
L9              5 S L7 AND BUFFER
L10             1 S L7 NOT L9
L11            1182 S DEPARAFFINIZ?
L12             3 S L11 AND (BISULFITE OR METABISULFITE)
L13            4572 S CELL CONDITION?
L14             0 S L13 AND (BISULFITE OR METABISULFITE)
L15            145 S CONDITION? SOLUTION?
L16             2 S L15 AND (BISULFITE OR METABISULFITE)
L17            1344 S ANTIGEN RETRIEVAL
L18             0 S L17 AND (BISULFITE OR METABISULFITE)
L19            6917 S EMBEDD? AND (REMOV? OR ETCH?)
L20             9 S L19 AND (BISULFITE OR METABISULFITE)
L21            25 S L6 AND CELL?
L22            20 DUP REMOV L21 (5 DUPLICATES REMOVED)
L23            0 S L6 AND CITRATE

```

=>

L Number	Hits	Search Text	DB	Time stamp
1	20	ventana adj medical\$.as.	USPAT; US-PGPUB	2002/04/25 08:13
2	9	(ventana adj medical\$.as.) and (bisulfite or metabisulfite)	USPAT; US-PGPUB	2002/04/25 08:21
3	0	((ventana adj medical\$.as.) and (bisulfite or metabisulfite)) and (sds or (sodium adj dodecyl))	USPAT; US-PGPUB	2002/04/25 08:21
4	440	435/40.5-40.52.ccls.	USPAT; US-PGPUB	2002/04/25 08:21
5	19	435/40.5-40.52.ccls. and (metabisulfite or bisulfite)	USPAT; US-PGPUB	2002/04/25 08:28
6	1	(435/40.5-40.52.ccls. and (metabisulfite or bisulfite)) and (sds or (sodium adj dodecyl))	USPAT; US-PGPUB	2002/04/25 08:29
7	119	(metabisulfite or bisulfite) same (sds or (sodium adj dodecyl))	USPAT; US-PGPUB	2002/04/25 08:29
8	33	((metabisulfite or bisulfite) same (sds or (sodium adj dodecyl))) and 435/\$.ccls.	USPAT; US-PGPUB	2002/04/25 08:30
9	33	((((metabisulfite or bisulfite) same (sds or (sodium adj dodecyl))) and 435/\$.ccls.) not (435/40.5-40.52.ccls. and (metabisulfite or bisulfite))	USPAT; US-PGPUB	2002/04/25 08:30
10	10	((metabisulfite or bisulfite) same (sds or (sodium adj dodecyl))) same glycol	USPAT; US-PGPUB	2002/04/25 09:10
11	601	deparaffiniz\$5	USPAT; US-PGPUB	2002/04/25 09:11
12	29	deparaffiniz\$5 and (metabisulfite or bisulfite)	USPAT; US-PGPUB	2002/04/25 09:12
13	4	deparaffiniz\$5 same (metabisulfite or bisulfite)	USPAT; US-PGPUB	2002/04/25 09:13
14	9	deparaffiniz\$5 same (sds or (sodium adj dodecyl))	USPAT; US-PGPUB	2002/04/25 09:16
15	1854	cell adj condition\$3	USPAT; US-PGPUB	2002/04/25 09:16
16	0	(cell adj condition\$3) same (bisulfite or metabisulfite)	USPAT; US-PGPUB	2002/04/25 09:17
17	10	(cell adj condition\$3) same citrate	USPAT; US-PGPUB	2002/04/25 09:17
18	1	((cell adj condition\$3) same citrate) same glycol	USPAT; US-PGPUB	2002/04/25 09:17
19	2	((cell adj condition\$3) same citrate) same (sds or (sodium adj dodecyl))	USPAT; US-PGPUB	2002/04/25 09:19
20	2474	condition\$3 adj solution\$1	USPAT; US-PGPUB	2002/04/25 09:19
21	35	(condition\$3 adj solution\$1) same (bisulfite or metabisulfite)	USPAT; US-PGPUB	2002/04/25 09:20
22	1	((condition\$3 adj solution\$1) same (bisulfite or metabisulfite)) same glycol	USPAT; US-PGPUB	2002/04/25 09:20
23	0	((condition\$3 adj solution\$1) same (bisulfite or metabisulfite)) same (sds or (sodium adj dodecyl))	USPAT; US-PGPUB	2002/04/25 09:20
24	0	((condition\$3 adj solution\$1) same (bisulfite or metabisulfite)) same citrate	USPAT; US-PGPUB	2002/04/25 09:21
25	81	antigen adj retrieval	USPAT; US-PGPUB	2002/04/25 09:21
26	0	(antigen adj retrieval) same (bisulfite or metabisulfite)	USPAT; US-PGPUB	2002/04/25 09:21
27	0	(antigen adj retrieval) same glycol	USPAT; US-PGPUB	2002/04/25 09:21
28	2	(antigen adj retrieval) same (sds or (sodium adj dodecyl))	USPAT; US-PGPUB	2002/04/25 09:22
29	3570	embedd\$3 near5 (remov\$3 or etch\$3)	USPAT; US-PGPUB	2002/04/25 09:23
30	0	(embedd\$3 near5 (remov\$3 or etch\$3)) same (bisulfite or metabisulfite)	USPAT; US-PGPUB	2002/04/25 09:23
31	1	(embedd\$3 near5 (remov\$3 or etch\$3)) same (sds or (sodium adj dodecyl))	USPAT; US-PGPUB	2002/04/25 09:23

WEST Search History

DATE: Thursday, April 25, 2002

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
side by side			result set

DB=JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=ADJ

L34	l32 and citrate	0	L34
L33	L32 and glycol	0	L33
L32	L30 and (sds or (sodium adj dodecyl))	31	L32
L31	L30 and (bisulfite or metabisulfite)	0	L31
L30	embedd\$3 near5 (remov\$3 or etch\$3)	1762	L30
L29	L27 and glycol	0	L29
L28	l27 and (bisulfite or metabisulfite)	0	L28
L27	antigen adj retrieval	5	L27
L26	L25 and glycol	1	L26
L25	L22 and (sds or (sodium adj dodecyl))	11	L25
L24	L2s and (sds or (sodium adj dodecyl))	5049	L24
L23	L22 and (bisulfite or metabisulfite)	2	L23
L22	condition\$3 adj solution\$1	331	L22
L21	L20 and glycol	0	L21
L20	L18 and (sds or (sodium adj dodecyl))	74	L20
L19	L18 and (bisulfite or metabisulfite)	0	L19
L18	cell adj condition\$3	361	L18
L17	L15 and (sds or (sodium adj dodecyl))	1	L17
L16	L15 and (bisulfite or metabisulfite)	0	L16
L15	deparaffiniz\$5	28	L15
L14	L11 and (sodium adj dodecyl)	0	L14
L13	L11 and citrate	8	L13
L12	L11 and (sds or (sodium adj dodecyl))	3	L12
L11	L10 and glycol	172	L11
L10	metabisulfite or bisulfite	4548	L10

DB=DWPI; PLUR=YES; OP=ADJ

L9	lemme-c-\$.in.	21	L9
L8	wo-9944030-\$.did.	1	L8
L7	wo-0014507-\$.did.	0	L7

DB=JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=ADJ

L6	wo-0014507-\$.did.	0	L6
----	--------------------	---	----

L5	utermohlen-j-\$.in.
L4	utermohlen-j-.in.
L3	utermohlen-j.in.
L2	towne-p-.in.
L1	towne-p-\$.in.

5	L5
0	L4
0	L3
1	L2
0	L1

END OF SEARCH HISTORY